9618 results
Cited 14 times since 2020 (2.9 per year)
source: EuropePMC
Annals of surgery,
Volume 272, Issue 5, 1 1 2020, Pages 678-683
Taking Morbidity and Mortality Conferences to a Next Level: The Resilience Engineering Concept.
Verhagen MJ, de Vos MS, Hamming JF
Objective: To explore possibilities to improve morbidity and mortality conferences using advancing insights in safety science. Summary background data: Mortality and Morbidity conferences (M&M) are the golden practice for case-based learning. While learning from complications is useful, M&M does not meet expectations for system-wide improvement. Resilience engineering principles may be used to improve M&M. Methods: After a review of the shortcomings of traditional M&M, resilience...
Abstract
Cited 13 times since 2020 (2.7 per year)
source: EuropePMC
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Volume 71, Issue 8, 1 1 2020, Pages 1847-1855
Dynamics of Intestinal Carriage of Extended-Spectrum Beta-lactamase-Producing Enterobacteriaceae in the Dutch General Population, 2014-2016.
van den Bunt G, Fluit AC, Bootsma MCJ, van Duijkeren E, Scharringa J, van Pelt W, Bonten MJM
Background: In the Netherlands, the prevalence of intestinal extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) carriage in community-dwelling subjects is ~5%. Little is known about the dynamics of ESBL-E carriage. Methods: In a nationwide, population-based study (2014-2016) with 4177 community-dwelling subjects, fecal samples from 656 subjects were collected after 1 (time point [T] = 1) and 6 (T = 2) months. The growth of ESBL-E was quantified and a whole-genome sequence ana...
Abstract
Cited 7 times since 2020 (1.5 per year)
source: EuropePMC
American journal of respiratory cell and molecular biology,
Volume 63, Issue 5, 1 1 2020, Pages 710-713
Decreased Glycolysis as Metabolic Fingerprint of Endothelial Cells in Chronic Thromboembolic Pulmonary Hypertension.
Smolders VFED, Rodríguez C, Morén C, Blanco I, Osorio J, Piccari L, Bonjoch C, Quax PHA, Peinado VI, Castellà M, Barberà JA, Cascante M, Tura-Ceide O
Abstract
Cited 14 times since 2020 (2.9 per year)
source: EuropePMC
Journal of orthopaedic trauma,
Volume 34 Suppl 3, 1 1 2020, Pages S15-S21
Factors Associated With Mortality After Surgical Management of Femoral Neck Fractures.
Bzovsky S, Comeau-Gauthier M, Schemitsch EH, Swiontkowski M, Heels-Ansdell D, Frihagen F, Bhandari M, Sprague S, FAITH Investigators, HEALTH Investigators
Background: Hip fractures are recognized as one of the most devastating injuries impacting older adults because of the complications that follow. Mortality rates postsurgery can range from 14% to 58% within one year of fracture. We aimed to identify factors associated with increased risk of mortality within 24 months of a femoral neck fracture in patients aged ≥50 years enrolled in the FAITH and HEALTH trials. Methods: Two multivariable Cox proportional hazards regressions were used to investiga...
Abstract
Cited 23 times since 2020 (4.8 per year)
source: EuropePMC
Annals of surgery,
Volume 272, Issue 5, 1 1 2020, Pages 773-778
Long-term Prognosis After Elective Abdominal Aortic Aneurysm Repair is Poor in Women and Men: The Challenges Remain.
Bulder RMA, Talvitie M, Bastiaannet E, Hamming JF, Hultgren R, Lindeman JHN
Objective: To evaluate the impact of changes in elective Abdominal Aortic Aneurysm (AAA) management on life-expectancy of AAA patients. Background: Over the past decades AAA repair underwent substantial changes, that is, the introduction of EVAR and implementation of intensified cardiovascular risk management. The question rises to what extent these changes improved longevity of AAA patients. Methods: National evaluation including all 12.907 (82.7% male) patients who underwent elective AAA repai...
Abstract
European heart journal,
Volume 41, Issue 43, 1 1 2020, Pages 4213
Anomalous origin of the left coronary artery from the pulmonary artery in a 72-year-old patient.
Kuneman JH, Fortuni F, van Dijkman PRM, Bax JJ
Abstract
Cited 1 times since 2020 (0.2 per year)
source: EuropePMC
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Volume 58, Issue 5, 1 1 2020, Pages 1105
What we see depends on what we look for.
Tomšič A, Klautz RJM
Abstract
Cited 107 times since 2020 (22.3 per year)
source: EuropePMC
European heart journal,
Volume 41, Issue 44, 1 1 2020, Pages 4245-4255
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, ODYSSEY OUTCOMES Investigators
Aims: Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. It is unknown if this relationship holds for total (first and subsequent) events. In the ODYSSEY OUTCOMES trial in patients with recent acute coronary syndrome (ACS), the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduced lipoprotein(a), low-density lipoprotein cholesterol (LDL-C), and cardiovascular events compared with placebo. This post hoc analysis determined whether...
Abstract
Cited 19 times since 2020 (4 per year)
source: EuropePMC
The Journal of antimicrobial chemotherapy,
Volume 75, Issue 11, 1 1 2020, Pages 3135-3143
Microevolution of acquired colistin resistance in Enterobacteriaceae from ICU patients receiving selective decontamination of the digestive tract.
Janssen AB, van Hout D, Bonten MJM, Willems RJL, van Schaik W
Background: Colistin is an antibiotic that targets the LPS molecules present in the membranes of Gram-negative bacteria. It is used as a last-resort drug to treat infections with MDR strains. Colistin is also used in selective decontamination of the digestive tract (SDD), a prophylactic therapy used in patients hospitalized in ICUs to selectively eradicate opportunistic pathogens in the oropharyngeal and gut microbiota. Objectives: To unravel the mechanisms of acquired colistin resistance in Gra...
Abstract
Cited 6 times since 2020 (1.3 per year)
source: EuropePMC
Clinical chemistry and laboratory medicine,
Volume 58, Issue 12, 1 1 2020, Pages 2099-2106
Stabilization patterns and variability of hs-CRP, NT-proBNP and ST2 during 1 year after acute coronary syndrome admission: results of the BIOMArCS study.
van den Berg VJ, Umans VAWM, Brankovic M, Oemrawsingh RM, Asselbergs FW, van der Harst P, Hoefer IE, Kietselaer B, Crijns HJGM, Lenderink T, Oude Ophuis AJ, van Schaik RH, Kardys I, Boersma E, Akkerhuis KM, BIOMArCS investigators
Objectives Details of the biological variability of high-sensitivity C-reactive protein (hs-CRP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and ST2 are currently lacking in patients with acute coronary syndrome (ACS) but are crucial knowledge when aiming to use these biomarkers for personalized risk prediction. In the current study, we report post-ACS kinetics and the variability of the hs-CRP, NT-proBNP and ST2. Methods BIOMArCS is a prospective, observational study with hi...
Abstract
Cited 15 times since 2020 (3.1 per year)
source: EuropePMC
Biochimica et biophysica acta. Reviews on cancer,
Volume 1875, Issue 1, 1 1 2020, Pages 188463
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
Del Re M, van Schaik RHN, Fogli S, Mathijssen RHJ, Cucchiara F, Capuano A, Scavone C, Jenster GW, Danesi R
Monoclonal antibodies that inhibit the programmed cell death protein 1 axis (anti-PD-1/PD-L1) are part of a new pharmacological strategy aimed at reinforcing the immune response to cancer. Despite the success in several cancer types, a significant percentage of patients do not benefit from treatment with these drugs due to intrinsic or acquired resistance or the occurrence of immune-related adverse reactions. Assessment of PD-L1 expression in tumor tissues is currently used to predict drug respo...
Abstract
Cited 31 times since 2020 (6.5 per year)
source: EuropePMC
European heart journal,
Volume 41, Issue 42, 1 1 2020, Pages 4114-4123
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG, ODYSSEY OUTCOMES Investigators
Aims: Statins reduce cardiovascular risk in patients with acute coronary syndrome (ACS) and normal-to-moderately impaired renal function. It is not known whether proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors provide similar benefit across a range of renal function. We determined whether effects of the PCSK9 inhibitor alirocumab to reduce cardiovascular events and death after ACS are influenced by renal function. Methods and results: ODYSSEY OUTCOMES compared alirocumab with pl...
Abstract
Cited 4 times since 2020 (0.8 per year)
source: EuropePMC
Journal of cardiovascular development and disease,
Volume 7, Issue 4, 1 1 2020, Pages E48
Assessment of D-Shaped Annulus of Mitral Valve in Patients with Severe MR Using Semi-Automated 4-Dimensional Analysis: Implications for Transcatheter Interventions.
Vo NM, van Wijngaarden SE, Marsan NA, Bax JJ, Delgado V
The development of transcatheter mitral valve replacement therapies requires accurate post-processing analysis tools to provide D-shaped mitral annulus dimensions from 3-dimensional (3D) data. The agreement between two semi-automated, software packages to process 3D transesophageal echocardiography (TEE) data for the measurement of the mitral valve annulus dimensions was evaluated. 3DTEE data of patients with moderate-severe mitral regurgitation (MR) were postprocessed with semi-automated, vendo...
Abstract
Cited 2 times since 2020 (0.4 per year)
source: EuropePMC
Journal of pediatric hematology/oncology,
Volume 42, Issue 8, 1 1 2020, Pages e712-e717
High-mobility Group Box 1 Protein in Pediatric Trauma Patients With Acute Traumatic Coagulopathy or Disseminated Intravascular Coagulation.
Ulusoy E, Duman M, Çağlar A, Küme T, Er A, Akgül F, Çitlenbik H, Yilmaz D, Ören H
Objectives: Trauma can induce the release of high-mobility group box 1 (HMGB1), which plays an important role in the activation of coagulation. In this study, we aimed to evaluate the role of HMGB1 in the early diagnosis of acute traumatic coagulopathy (ATC), disseminated intravascular coagulation, and clinical course. Materials and methods: One hundred pediatric trauma patients and 50 healthy controls were enrolled. Demographic data, physical examination results, trauma scores, International So...
Abstract
Cited 2 times since 2020 (0.4 per year)
source: EuropePMC
World journal for pediatric & congenital heart surgery,
Volume 11, Issue 6, 1 1 2020, Pages 742-747
Long-Term Follow-Up of Pericardium for the Ventricular Component in Atrioventricular Septal Defect Repair.
IJsselhof RJ, Duchateau SDR, Schouten RM, Slieker MG, Hazekamp MG, Schoof PH
Background: Despite the improved outcome in complete atrioventricular septal defect (AVSD) repair, reoperations for left atrioventricular valve (LAVV) dysfunction are common. The aim of this study was to evaluate the effect of fresh untreated autologous pericardium for ventricular septal defect (VSD) closure on atrioventricular valve function and compare the results with the use of treated bovine pericardial patch material. Methods: Clinical and echocardiographic data were collected of patients...
Abstract
Cited 49 times since 2020 (10.2 per year)
source: EuropePMC
European heart journal,
Volume 41, Issue 43, 1 1 2020, Pages 4181-4187
Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial.
van Andel MM, Indrakusuma R, Jalalzadeh H, Balm R, Timmermans J, Scholte AJ, van den Berg MP, Zwinderman AH, Mulder BJM, de Waard V, Groenink M
Aims: The COMPARE trial showed a small but significant beneficial effect of 3-year losartan treatment on aortic root dilatation rate in adults with Marfan syndrome (MFS). However, no significant effect was found on clinical endpoints, possibly due to a short follow-up period. The aim of the current study was therefore to investigate the long-term clinical outcomes after losartan treatment. Methods and results: In the original COMPARE study (inclusion 2008-2009), adult patients with MFS (n = 233)...
Abstract
Cited 19 times since 2020 (4 per year)
source: EuropePMC
Journal of orthopaedic trauma,
Volume 34 Suppl 3, 1 1 2020, Pages S70-S75
Venous Thromboembolism in Hip Fracture Patients: A Subanalysis of the FAITH and HEALTH Trials.
MacDonald DRW, Neilly D, Schneider PS, Bzovsky S, Sprague S, Axelrod D, Poolman RW, Frihagen F, Bhandari M, Swiontkowski M, Schemitsch EH, Stevenson IM, FAITH Investigators, HEALTH Investigators
Background: The primary objective of this study was to determine the incidence of symptomatic venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), in the hip fracture population. Secondary objectives included determining timing of VTE diagnosis, VTE thromboprophylaxis given, and identifying any factors associated with VTE. Methods: Using data from the FAITH and HEALTH trials, the incidence of VTE, including DVT and PE, and the timing of VTE were determi...
Abstract
Cited 26 times since 2020 (5.4 per year)
source: EuropePMC
Molecular oncology,
Volume 15, Issue 1, 31 5 2020, Pages 57-66
Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA.
Bos MK, Nasserinejad K, Jansen MPHM, Angus L, Atmodimedjo PN, de Jonge E, Dinjens WNM, van Schaik RHN, Del Re M, Dubbink HJ, Sleijfer S, Martens JWM
Quantification of tumor-specific variants (TSVs) in cell-free DNA is rapidly evolving as a prognostic and predictive tool in patients with cancer. Currently, both variant allele frequency (VAF) and number of mutant molecules per mL plasma are used as units of measurement to report those TSVs. However, it is unknown to what extent both units of measurement agree and what are the factors underlying an existing disagreement. To study the agreement between VAF and mutant molecules in current clinica...
Abstract
Cited 10 times since 2020 (2.1 per year)
source: EuropePMC
Pediatric nephrology (Berlin, Germany),
Volume 36, Issue 5, 31 5 2020, Pages 1195-1205
Predictors of poor kidney outcome in children with C3 glomerulopathy.
Pınarbaşı AS, Dursun I, Gokce I, Çomak E, Saygılı S, Bayram MT, Donmez O, Melek E, Tekcan D, Çiçek N, Yılmaz D, Tabel Y, Yıldırım ZY, Bahat E, Koyun M, Soylu A, Canpolat N, Aksu B, Çelakıl ME, Taşdemir M, Benzer M, Özçelik G, Bakkaloğlu SA, Düşünsel R
Background: C3 glomerulopathy (C3G) is characterized by heterogeneous clinical presentation, outcome, and predominant C3 accumulation in glomeruli without significant IgG. There is scarce outcome data regarding childhood C3G. We describe clinical and pathological features, treatment and outcomes, and risk factors for progression to chronic kidney disease stage 5 (CKD5) in the largest pediatric series with biopsy-proven C3G. Methods: Sixty pediatric patients with C3G from 21 referral centers in T...
Abstract
Cited 10 times since 2020 (2.1 per year)
source: EuropePMC
Cancers,
Volume 12, Issue 11, 29 5 2020, Pages E3179
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer.
Steendam CMJ, Veerman GDM, Pruis MA, Atmodimedjo P, Paats MS, van der Leest C, von der Thüsen JH, Yick DCY, Oomen-de Hoop E, Koolen SLW, Dinjens WNM, van Schaik RHN, Mathijssen RHJ, Aerts JGJV, Dubbink HJ, Dingemans AC
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC), not all patients benefit. We therefore explored the impact of the presence of mutations found in cell-free DNA (cfDNA) and TKI plasma concentrations during treatment on progression-free survival (PFS). In the prospective START-TKI study blood samples from 41 patients with EGFR-mutated NSCLC treated with EGFR-TKIs were av...
Abstract
